Celularity (NASDAQ:CELU) Upgraded at Wall Street Zen

Celularity (NASDAQ:CELU) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings upgraded shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Celularity presently has an average rating of “Sell”.

Celularity Stock Down 8.0%

Shares of CELU stock opened at $0.63 on Friday. The stock has a 50-day moving average price of $1.18 and a 200 day moving average price of $1.06. The firm has a market cap of $20.45 million, a price-to-earnings ratio of -0.37 and a beta of 0.88. Celularity has a 12 month low of $0.56 and a 12 month high of $2.55.

Celularity (NASDAQ:CELU) last released its earnings results on Tuesday, October 20th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $5.43 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Celularity stock. C V Starr & Co. Inc. acquired a new stake in shares of Celularity, Inc. (NASDAQ:CELU) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity makes up 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th largest position. C V Starr & Co. Inc. owned approximately 2.64% of Celularity at the end of the most recent quarter. Hedge funds and other institutional investors own 19.02% of the company’s stock.

Celularity Company Profile

Celularity, Inc. (NASDAQ: CELU) is a biotechnology company developing and commercializing therapies and biomaterial products derived from human placental tissue. Its work focuses on regenerative medicine and cellular therapy, including allogeneic, or donor-derived, cell products intended for applications in oncology, immune-mediated diseases, and tissue repair. The company’s research pipeline has included placenta-derived natural killer (NK) cell therapies, such as CYNK-001, an investigational product studied for certain blood cancers, and other cell-based programs designed to address cancer and inflammatory conditions.